Moneycontrol

Budget 2023Budget 2023

PARTNERS

  • Tata AIA Life Insurance
  • Hafele
  • Motilal Oswal
Live Now : Nifty Banker 3.0 | India's First Retail Index Traders Online Conference.
Budget 2023
Budget 2023
you are here: HomeNewsBusiness

Dr Reddy's terminates Kuwait clinical trial of favipiravir on moderate to severe COVID-19 patients

The data from the Kuwait study involving moderate-severe COVID-19 hospitalized patients did not show statistically significant difference for the primary endpoint or the time taken to resolve hypoxia. However, low risk category COVID-19 patients on the broad spectrum antiviral got discharged three days ahead of the placebo group.

January 27, 2021 / 06:56 PM IST
Representative image

Representative image

 
 
live
  • bselive
  • nselive
Volume
Todays L/H
More

Dr Reddy’s Laboratories and Global Response Aid (GRA) on January 27 announced the termination of Avigan (favipiravir) clinical trial conducted in Kuwait on moderate to severe COVID-19 patients in a hospital setting, as the data failed to show a statistically significant difference for the primary endpoint.

The data from the Kuwait study involving moderate-severe COVID-19 hospitalised patients did not show a statistically significant difference for the primary endpoint or the time taken to resolve hypoxia. However, low-risk category COVID-19 patients on the broad spectrum antiviral got discharged three days ahead of the placebo group.

GRA is an alliance focused on improving medical supply chain worldwide. Hypoxia is a condition in which the body is deprived of adequate oxygen supply. Hypoxia is the major symptom in patients with moderate-severe COVID-19.

While it took seven days or a day less than placebo for resolution of hypoxia in the Avigan arm.